Abstract: A method and system is used to locate tissue for removal during a resection. The system includes a container that holds a photoactivatable agent capable of binding with unwanted tissue at a treatment site, a light source, and a viewing device. The light source is adapted to continuously output light that causes fluorescence of the photoactivatable agent in unwanted tissue. The system provides fluorescence-enhanced viewing of the treatment site through the viewing device. The viewing device has a filter that filters out light from the light source that is reflected from the treatment site while allowing a fluorescence emission from the photoactivatable agent to pass therethrough to each eye of the user. The light from the light source and the fluorescence emission are in different regions of the energy spectrum.

Abstract: Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member.

Abstract: The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy (“PDT”) of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizing agent or a photosensitizing agent delivery system or prodrug, where the photosensitizing agent or photosensitizing agent delivery system or prodrug selectively binds to the target tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent or if prodrug, by a prodrug product thereof, where the light is provided by a light source, and where the irradiation is at low fluence rate that results in the activation of the photosensitizing agent or prodrug product.

Abstract: Light generating devices for illuminating portions of vascular tissue, to render photodynamic therapy. In one embodiment, a light source array preferably including a plurality of light emitting diodes, a focusing lens, and a light diffusing element are included in a distal end of a catheter. A balloon is optionally provided to interrupt blood flow that can block the transmission of light, and to center the apparatus in a blood vessel. Optical fibers optionally direct light from the light source to the diffusing element. The light source array can have a radial or linear configuration and can produce more than one wavelength of light for activating different photoreactive agents. Linear light source elements are particularly useful to treat elongate portions of tissue in a vessel. One embodiment intended for use with a conventional balloon catheter integrates light sources into a guidewire.

Abstract: The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced.

Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.

Abstract: Methods of treating diseases of a subject through selective occlusion of blood vessels. The methods include identifying and/or mapping the blood vessels supplying nutrients to the diseased or unwanted tissue, delivering an appropriate dose of an occlusion-forming photosensitizer to the subject, and exciting the photosensitizer with sufficient light irradiation in the vicinity of the blood vessels to cause vessel occlusion. The vessel occlusion cuts off nutrient supply to the diseased or unwanted tissue resulting in cell death of that tissue and any other tissue served by the occluded vessels.

Abstract: The present invention is drawn to apparatus for transcutaneous photodynamic therapy (“PDT”) of a target tissue or compositions in a mammalian subject, which includes a light source that is external to the subject and is selected from among one or a plurality of laser diodes; light emitting diodes; electroluminescent light source; incandescent light sources; cold cathode fluorescent light sources; organic polymer light sources; or inorganic light sources, where the light source is adapted to direct the light in a direction lengthwise and parallel to a vessel wall comprising the lesion.

Abstract: Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member.

Abstract: The present invention is drawn to energy activated targeted delivery systems for administering a therapy to a target tissue or target composition in a mammalian subject, using an energy source that preferably transmits energy to a treatment site transcutaneously. The systems provide for administering to the subject a therapeutically effective amount of a targeted substance, which preferably selectively binds to the target tissue. Energy at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The energy intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted energy-activated agent or targeted prodrug product.

Abstract: Light sources are incorporated into a guidewire for enabling the ability to render light therapy be added to catheters that do not have that capability. In one exemplary embodiment, a solid guidewire includes a conductive core, and light sources are added to compartments formed in a distal end of the guidewire. In another exemplary embodiment, a light source array is included in a distal end of a hollow guidewire. A plurality of openings are formed into the walls of the hollow guidewire surrounding the array, enabling light to pass through the openings. Conductors extend from the array though the hollow center of the guidewire, to a proximal end of the hollow guidewire. The hollow guidewire can be coated with a conductive material, so that the coating on the guidewire serves as a conductor.

Abstract: Light generating devices for illuminating portions of vascular tissue, to render photodynamic therapy. In one embodiment, a light source array preferably including a plurality of light emitting diodes, a focusing lens, and a light diffusing element are included in a distal end of a catheter. A balloon is optionally provided to interrupt blood flow that can block the transmission of light, and to center the apparatus in a blood vessel. Optical fibers optionally direct light from the light source to the diffusing element. The light source array can have a radial or linear configuration and can produce more than one wavelength of light for activating different photoreactive agents. Linear light source elements are particularly useful to treat elongate portions of tissue in a vessel. One embodiment intended for use with a conventional balloon catheter integrates light sources into a guidewire.

Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.

Abstract: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.

Abstract: A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.

Abstract: A system and method for excitation of photosensitizers is configured to provide desired illumination on targeted eye tissue. The excitation system includes an optical module that generates illumination and a controller to power the optical module and control the shape, intensity or energy level, and duration of the illumination. The optical module includes a contact portion for interfacing with the eye, a treatment beam portion including a light emitter array to generate shaped light patterns and optics to focus the light patterns onto the eye, and a visualization portion to provide visual feedback of treatment through a visualization interface coupled with a microscope. A typical treatment involves the optical module being placed on a diseased eye of a patient by a clinician to project illumination on a diseased portion of the eye. The clinician typically views the eye through the microscope and the optical module during treatment.

Abstract: Light generating devices for illuminating portions of vascular tissue, to render photodynamic therapy. In one embodiment, a light source array preferably including a plurality of light emitting diodes, a focusing lens, and a light diffusing element are included in a distal end of a catheter. A balloon is optionally provided to interrupt blood flow that can block the transmission of light, and to center the apparatus in a blood vessel. Optical fibers optionally direct light from the light source to the diffusing element. The light source array can have a radial or linear configuration and can produce more than one wavelength of light for activating different photoreactive agents. Linear light source elements are particularly useful to treat elongate portions of tissue in a vessel. One embodiment intended for use with a conventional balloon catheter integrates light sources into a guidewire.